Other Events ·
The European Commission approved an extension of the indication for MenQuadfi to include infants from six weeks of age…
SNYNFSanofi
The European Commission approved an extension of the indication for MenQuadfi to include infants from six weeks of age against invasive meningococcal disease, expanding its previous approval for individuals aged 12 months and older. This regulatory milestone follows a positive opinion from the Committee for Medicinal Products for Human Use on June 25, 2026, and is supported by immunogenicity data from the MET58 pivotal clinical study involving over 6,000 infants across 11 countries. The approval allows for new dosing regimens aligned with routine infant immunization schedules, including a 2+1 schedule for standard risk and a 3+1 schedule for high-risk exposure to serogroup A. Sanofi is an R&D driven biopharmaceutical company focused on developing vaccines and medicines to improve public health outcomes globally.